Inactive Instrument

Harpoon Therapeutics, Inc.

Equities

HARP

US41358P2056

Biotechnology & Medical Research

Harpoon Therapeutics, Inc. Appoints William E. Picht, Jr. as Chief Financial Officer

January 26, 2017 at 08:30 am

Harpoon Therapeutics, Inc. announced the appointment of William E. Picht, Jr. as chief financial officer. Mr. Picht brings more than 25 years of industry experience in strategic finance, operations, investor relations, business planning and oversight. Most recently, he served as chief financial officer for Pearl Therapeutics.

Latest news about Harpoon Therapeutics, Inc.

Global markets live: Domino's Pizza, Generali, Oracle, Intel, Boeing...	03-12
Wall Street: start of the week down before CPI	03-11	CF
Merck Completes Acquisition of Harpoon Therapeutics	03-11	MT
Merck: acquisition of Harpoon Therapeutics finalized	03-11	CF
Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from NASDAQ Composite Index	03-10	CI
Merck Sharp & Dohme LLC completed the acquisition of Harpoon Therapeutics, Inc..	03-10	CI
Harpoon Therapeutics, Inc.(NasdaqCM:HARP) dropped from S&P TMI Index	03-10	CI
North American Morning Briefing : Stock Futures -2-	02-27	DJ
Citigroup Downgrades Harpoon Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $13	02-26	MT
Sanofi to Buy Assets From Inhibrx in Deal Valued at Up to $2.2 Billion -- Update	01-23	DJ
Arix Bioscience eyes USD19 million return from Harpoon sale	01-19	AN
Arix Bioscience Flags Proceeds from Merck's Purchase of Harpoon Therapeutics	01-19	MT
North American Morning Briefing : Central Bankers -2-	01-17	DJ
North American Morning Briefing : Samsung Warning -2-	01-09	DJ
Arix Bioscience's Portfolio Company Signs $680 Million Takeover Deal with Merck & Co.	01-08	MT
Merck Agrees to Buy Harpoon Therapeutics in $680 Million Deal	01-08	MT
Trending : Johnson & Johnson and Merck & Co. Announce Acquisitions	01-08	DJ
Canaccord Genuity Downgrades Harpoon Therapeutics to Hold From Buy, Cuts Price Target to $23 From $30	01-08	MT
HC Wainwright Downgrades Harpoon Therapeutics to Neutral From Buy, Adjusts Price Target to $23 From $12	01-08	MT
Top Midday Gainers	01-08	MT
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	01-08
Investors lower their expectations	01-08
Drugmakers kick off industry conference with two cancer deals	01-08	RE
Sector Update: Health Care Stocks Mixed Premarket Monday	01-08	MT
Sector Update: Health Care	01-08	MT

Chart Harpoon Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company's TriTAC product candidates include HPN217, and HPN328. The Company's ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	126B
REGENERON PHARMACEUTICALS, INC.	+24.67%	118B
ARGENX SE	+23.55%	27.87B
BIONTECH SE	-17.74%	20.95B
GENMAB A/S	-16.15%	16.92B
BEIGENE, LTD.	-15.21%	16.18B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.79B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.08B

Bio Therapeutic Drugs